Overview

Intratumoral CAN1012 in Subjects With Solid Tumors

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.
Phase:
Phase 1
Details
Lead Sponsor:
CanWell Pharma Inc.